文献速递银屑病与炎症性皮肤病

美国国家银屑病基金会GLP-1受体激动剂治疗银屑病入门综述

The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
PubMed 文献 · JAMA Dermatol · 2026-01-01

该综述由美国国家银屑病基金会医学委员会撰写,旨在向皮肤科医生介绍GLP-1受体激动剂(GLP-1 RAs)用于银屑病治疗。现有证据显示GLP-1 RAs与PASI评分相对下降约40%至80%相关,尤其肥胖或2型糖尿病患者,但研究多为小样本(7-48例)、短期(≤6个月)、无对照。目前证据支持在特定代谢共病患者中考虑辅助使用,确定性结论需等待更大规模随机临床试验。

要点

  • GLP-1 RAs与银屑病PASI评分相对下降约40%至80%相关,并伴生活质量改善。
  • 现有研究多为小样本、短期、无对照,证据级别有限。
  • GLP-1 RAs可与甲氨蝶呤、环孢素和生物制剂安全联用。

核心结论

  • GLP-1 RAs靶向银屑病共享的代谢和炎症通路。
  • 当前证据支持在特定代谢共病患者中考虑辅助使用。
  • 确定性结论需等待更大规模随机临床试验。

研究设计与样本

  • 美国国家银屑病基金会医学委员会撰写的叙述性综述。
  • 旨在提供证据知情整合和实用考虑,向皮肤科医生介绍GLP-1 RAs。

主要发现

  • GLP-1 RAs与PASI评分相对下降约40%至80%相关,尤其肥胖或2型糖尿病患者。
  • 司美格鲁肽和利拉鲁肽与C反应蛋白、白细胞介素-6、血脂和内脏脂肪减少相关。
  • 在小规模转化队列中,PASI改善与浅表脂肪和真皮γδ T细胞密度减少相关。
  • 不良事件主要为短暂胃肠道症状,胰腺炎和胆囊事件罕见。

关键数值与推荐

  • 研究报道PASI相对下降范围约40%至80%。
  • 多数研究样本量7-48例,短期≤6个月,缺乏对照组。

临床怎么用

  • 在具有代谢共病的特定银屑病患者中可考虑辅助使用GLP-1 RAs。
  • GLP-1 RAs可与甲氨蝶呤、环孢素和生物制剂联合使用。

局限性

  • 现有研究多为小样本、短期、无对照设计。
  • 需更大规模随机临床试验确认疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis is a chronic immune-mediated disease associated with cardiovascular, metabolic, musculoskeletal, psychiatric, hepatic, kidney, and pulmonary comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved by the US Food and Drug Administration for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis-conditions common in psoriasis. Emerging evidence suggests GLP-1 RAs and dual glucose-dependent insulinotropic polypeptide/GLP-1 agonists may improve psoriatic skin disease, partly through immune modulation. If confirmed in larger randomized clinical trials, GLP-1-based therapies may offer an opportunity to address both cutaneous disease and cardiometabolic comorbidities. This primer from the US National Psoriasis Foundation Medical Board sought to provide an evidence-informed narrative synthesis and practical considerations to introduce dermatologists to GLP-1 RAs for psoriasis treatment. OBSERVATIONS: GLP-1 RAs have been associated with reductions in Psoriasis Area and Severity Index (PASI) scores, particularly in patients with obesity or type 2 diabetes. Studies report relative PASI reductions ranging from approximately 40% to 80% with parallel quality-of-life gains, although most of these studies are small (7-48 patients), short term (≤6 months), and lack a control group. Semaglutide and liraglutide have been associated with reductions in C-reactive protein, interleukin-6, lipids, and visceral adiposity. In small, translational cohorts, PASI improvement has been correlated with reductions in superficial adiposity and dermal γδ T-cell density. GLP-1 RAs combine safely with methotrexate, cyclosporine, and biologics. Adverse effects are mainly transient gastrointestinal symptoms; pancreatitis and gallbladder events are rare. Early data show both metabolic and immunomodulatory benefits. CONCLUSIONS AND RELEVANCE: This review found that GLP-1-based therapies target shared metabolic and inflammatory pathways in psoriasis. Current evidence supports consideration of adjunctive use in selected patients with metabolic comorbidities, although definitive conclusions await larger randomized clinical trials.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Sheth S, Merola JF, Weber BN, et al. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review. JAMA Dermatol. 2026. PMID: 42054048. doi:10.1001/jamadermatol.2026.0859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。